187.5	mm	35 mm	157.5 mm
		P G P I O 1 1 3 E Rosuvastatin Calcium Tablets	
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ROSUVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN CALCIUM TABLETS. ROSUVASTATIN CALCIUM tablets, for oral use Initial U.S. Approval: 2003 RECENT MAJOR CHANGES- Dosage and Administration, Use with Concomitant Therapy (2.4) 5/2020 Warning and Precautions, Skeletal Muscle Effects (5.1) 5/2020 Warning and Precautions, Immune-Mediated Necrotizing Myopathy (5.2) 9/2020	 Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Perform liver enzyme tests before initiating therapy and as clinically indicated thereafter. (5.3) ADVERSE REACTIONS	 5.5 Proteinuria and Hematuria In the rosuvastatin clinical trial program, dipstick-positive proteinuria and microscopic hematuria were damong rosuvastatin treated patients. These findings were more frequent in patients taking rosuvastati when compared to lower doses of rosuvastatin or comparator HMG-CoA reductase inhibitors, thoug generally transient and was not associated with worsening renal function. Although the clinical significan finding is unknown, a dose reduction should be considered for patients on rosuvastatin therapy with une persistent proteinuria and/or hematuria during routine urinalysis testing. 5.6 Endocrine Effects Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase in including rosuvastatin. Based on clinical trial data with rosuvastatin, in some instances these increas exceed the threshold for the diagnosis of diabetes mellitus [see Adverse Reactions (6.1)]. Athough clinical studies have shown that rosuvastatin alone does not reduce basal plasma concentration or impair adrenal reserve, caution should be exorisions (6.1)]. Athough clinical studies that may decrease the levels or activity of endogenous steroid hormones ketoconazole, spironolactone, and cimetidine. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: 9. Readwarge and Precautions (6.1)] 9. Liver enzyme abnormalities [see Varrings and Precautions (5.3)] C1 Clinical Studies Experience 1. myalgia and a cuice renal failure and myopathy (including relevent duration of 15 weeks, 1.4% of patients discontinued due to adverse reactions. The most or adverse reactions that led to treatment discontinuation were: 9. myalgia 9. abdominal pain 9. nausea 	40 mg, including rosuvastatin, coadministered with colchicine, and caution should be exercised when prescribing rosuvastatin with colchicine [see Warnings and Precautions (5.1)]. 8 USEIN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Rosuvastatin is contraindicated for use in pregnant women since safety in pregnant women has not beer established and there is no apparent benefit to therapy with rosuvastatin during pregnancy. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, rosuvastatin may cause fetal harm when administered to pregnant women fastered to pregnant women fastered to pregnant women fastered to pregnant women fastered to a maximum recommended human dose (MRHD) of 40 mg/day in rats or rabbits (based on AUC and body surface area respectively). In rats and rabbits, decreased pup/fetal survival occurred at 12 times and equivalent, respectively to the MRHD of 40 mg/day [see Data]. vositisi Data Maman data Limited published data on rosuvastatin have not shown an increased risk of major congenital malformations on miscarriage. Rare reports of congenital anomalies, spontaneous abortions, and fetal deaths/stillibriths did no exceed what would be expected in the general population. The unber of cases is adequate to exclude a > 3 to 4 foid increase: in congenital anomalies, spontaneous abortinos, and fetal deaths/stillibriths did no exceed what would be expected in the general population. The number of cases is adequate to exclude a > 3 to 4 foid increase in congenital anomalies, spontaneous abortinos, and fetal deaths/stillibriths did no exceed what would be expected in the general population. The number of cases
 CONTRAINDICATIONS Known hypersensitivity to product components (4) Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4) Pregnancy (4, 8.1, 8.3) Lactation (4, 8.2) 	 USE IN SPECIFIC POPULATIONS- Females of reproductive potential: Advise females of reproductive potential to use effective contraception during treatment with rosuvastatin. (8.3) Severe renal impairment (not on hemodialysis): Starting dose is 5 mg, not to exceed 10 mg. (2.5, 5.1, 8.6) Asian population: Consider 5 mg starting dose. (2.3, 8.8) 	Reactions 5 mg 10 mg 20 mg 40 mg Rosuvastatin N N=291 N=283 N=64 N=106 5 mg to 40 mg 40 mg	In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the humar exposure at the MRHD dose of 40 mg/day based on AUC). acebo = 382 In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD or 40 mg/day based body surface area).
 WARNINGS AND PRECAUTIONS	See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information. Revised: 11/2020	Nausea 3.8 3.5 6.3 0 3.4 Myalgia 3.1 2.1 6.3 1.9 2.8 Asthenia 2.4 3.2 4.7 0.9 2.7	Ve also Contraception (5.5)]; Rosuvastatin may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (s. 7)]. Advise females of reproductive potential to use effective contraception during treatment with rosuvastatin. 8.4 Pediatric Use Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca's CRESTOF

Safety Related Changes), Add USP Claim

Artwork Type: **PACKAGE OUTSERT**

Void A/W Reason: CHANGE IN TEXT

AS PER RA DRAFT (RLD Revision,

Dimension: 380x570 mm

Artwork Code: PGPI0113E

Void Code: PGPI0113D

Country: ANDA-US

 \bigcirc

SUN PHARMA

Rosuvastatin calcium tab

FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE Hypertriglyceridemia Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Adult Patients with Homozygous Familial Hypercholesterolemia 15 Limitations of Use 2 DOSAGE AND ADMINISTRATION

General Dosing Information Dosing in Asian Patients Use with Concomitant Therapy Table 2. Adverse Reactions' Reported in $\ge 2\%$ of Patients 1

Ad

Table	2. Adverse Reactions Reported in 2% of Patients fre	a
	Rosuvastatin and $>$ Placebo in a Trial (% of Patients)

Rosuvastatin a	nd > Placebo in a Trial (%	of Patients)
verse Reactions	Rosuvastatin 40 mg N=700	Placebo N=281
valgia	12.7	12.1
thralgia	10.1	7.1
adache	6.4	5.3
ziness	4.0	2.8
reased CPK	2.6	0.7

698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be

Elderly patients are at higher risk of myopathy and rosuvastatin should be prescribed with caution in the elderly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

8.6 Renal Impairment

Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CL_{er} > 30 mL/min/ 1.73 m³). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CL_w <30 mL/min/1.73 m²) who are not receiving hemodialysis and dose adjustment is required [see ation (2.5), Warnings and Precautions (5.1) and Clinical Pharm

Language: ENGLISH Mfg. Location: DADRA Specification/Type of Paper: **SUPER FINE 41 GSM ITC PAPER** Folding:

Remark (if any):

Checked by:


Approved by:

Approved by RA:

APPROVAL HISTORY ATTACHED

No. of Colors: 1

Black



2.5 Dosing in Patients with Severe DOSAGE FORMS AND STRENGTHS 12.2 Pharmacodynamics CONTRAINDICATIONS WARNINGS AND PRECAUTIONS 12.3 Pharmacokinetics 12.5 Pharmacogen Skeletal Muscle Effects 13 NONCLINICAL TOXICOLOGY Immune-Mediated Necrotizing Myopathy 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2 Animal Toxicology and/or Pharmacology Liver Enzyme Abnormalities 5.3 Concomitant Coumarin Anticoagulants 14 CLINICAL STUDIES Proteinuria and Hematuria 14.3 Hypertriglyceridemia14.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) 5.6 Endocrine Effects ADVERSE REACTIONS 14.5 Homozygous Familial Hyperch Clinical Studies Experience Postmarketing Experience HOW SUPPLIED/STORAGE AND HANDLING PATIENT COUNSELING INFORMATION DRUG INTERACTIONS Cyclosporine * Sections or subsections omitted from the full prescribing information are not listed. emfibrozi Anti-viral Medications Darolutamide 7.5 Regorafenib 7.6 Coumarin Anticoagulants Niacin 7.8 Fenofibrate 7.9 Colchicine FULL PRESCRIBING INFORMATION 20 mg tablets: Pink colored, circular, biconvex, film-coated tablets with '584' debossed on one side and plain on the other side of the tablet INDICATIONS AND USAGE 40 mg tablets: Pink colored, oval, biconvex, film-coated tablets with '585' debossed on one side and plain on the Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug other side of the tablet luct is not labeled with that pediatric information CONTRAINDICATIONS Rosuvastatin is contraindicated in the following conditions 1.3 Hypertriglyceridemia Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin [see Adverse Reactions astatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. Patients with active liver disease, which may include unexplained persistent elevations of hepatic 1.4 Primary Dysbetalipoproteinemia (Type III Hyperlipopr transaminase levels [see Warnings and Precautions (5.3)]. Rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary Pregnancy [see Use in Specific Populations (8.1, 8.3)]. dysbetalipoproteinemia (Type III Hyperlipoproteinemia Lactation. Limited data indicate that rosuvastatin calcium is present in human milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require rosuvastatin calcium tablets 1.5 Adult Patients with Homozygous Familial Hypercholesterolemia treatment should not breastfeed their infants [see Use in Specific Populations (8.2)]. statin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult atients with homozygous familial hypercholesterolemia WARNINGS AND PRECAUTIONS 1.8 Limitations of Use 5.1 Skeletal Muscle Effects losuvastatin calcium tablets have not been studied in Fredrickson Type I and V dyslipidemias. Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including rosuvastatin. These risks can occur at any dose evel, but are increased at the highest dose (40 mg). 2 DOSAGE AND ADMINISTRATION Rosuvastatin should be prescribed with caution in patients with predisposing factors for myopathy 2.1 General Dosing Information The dose range for rosuvastatin calcium tablets in adults is 5 mg to 40 mg orally once daily. The usual starting (e.g., age \geq 65 years, inadequately treated hypothyroidism, renal impairment). dose is 10 mg to 20 mg once daily. The usual starting dose in adult patients with homozygous familial The risk of myopathy during treatment with rosuvastatin may be increased with concurrent administration of gemfibrozil, some other lipid-lowering therapies (other fibrates or niacin), cyclosporine, darolutamide, egorafenib, atazanavir/ritonavir, lopinavir/ritonavir, simeprevir or combination of sofosbuvir/ velpatasvir, The maximum rosuvastatin calcium tablets dose of 40 mg should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose [see Warnings and Precautions (5.1)]. voxilaprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/ pibrentasvir, all combinations with ledipasvir (including ledipasvir/sofosbuvir) [see Dosage and Administration (2) and Drug Interactions (7)]. Cases of myopathy, including rhabdomyolysis, have been reported with HMG Rosuvastatin calcium tablets can be administered as a single dose at any time of day, with or without food. The CoA reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be tablet should be swallowed whole exercised when prescribing rosuvastatin with colchicine [see Drug Interactions (7.9)]. When initiating rosuvastatin calcium tablets therapy or switching from another HMG-CoA reductase inhibitor Rosuvastatin therapy should be discontinued if markedly elevated creatine kinase levels occur or myopathy is therapy, the appropriate rosuvastatin calcium tablets starting dose should first be utilized, and only then titrated diagnosed or suspected. Rosuvastatin therapy should also be temporarily withheld in any patient with an acute, according to the patient's response and individualized goal of therapy. serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to habdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, After initiation or upon titration of rosuvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and electrolyte disorders, or uncontrolled seizures) and the dosage adjusted accordingly. All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after product is not labeled with that pediatric information. discontinuing rosuvastatin 5.2 Immune-Mediated Necrotizing Myopathy There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, 2.3 Dosing in Asian Patient In Asian patients, consider initiation of rosuvastatin calcium tablets therapy with 5 mg once daily due to increased rosuvastatin plasma concentrations. The increased systemic exposure should be taken into consideration when treating Asian patients not adequately controlled at doses up to 20 mg/day [see Use in Specific Populations (8.8) associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine inase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; and Clinical Pharmacology (12.3)]. muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional

USE IN SPECIFIC POPULATIONS

Females and Males of Reproductive Potential

Pregnancy

8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment

CLINICAL PHARMACOLOGY

Asian Patients

Mechanism of Action

8.4 Pediatric Use

OVERDOSAGE DESCRIPTION

8.1 8.2 Lactation

8.3

2.4 Use with Concomitant Therapy

Patients taking cyclosporine and darolutamide The dose of rosuvastatin calcium tablets should not exceed 5 mg once daily [see Warnings and Precautions (5.1), Drug Interactions (7.1), Drug Interactions (7.4) and Clinical Pharmacology (12.3)].

Patients taking gemfibrozil

Avoid concomitant use of rosuvastatin calcium tablets with gemfibrozil. If concomitant use cannot be avoided, initiate rosuvastatin calcium tablets at 5 mg once daily. The dose of rosuvastatin calcium tablets should not exceed 10 mg once daily [see Warnings and Precautions (5.1), Drug Interactions (7.2) and Clinical rmacology (12.3)]

Patients taking regorafenib

Concomitant use of rosuvastatin calcium tablets and regorafenib, the dose of rosuvastatin calcium tablets should not exceed 10 mg once daily. [see Warnings and Precautions (5.1), Drug Interactions (7.5) and Clinical armacology (12.3)]

Patients taking atazanavir and ritonavir, lopinavir and ritonavir, simeprevir or combination of dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir

Initiate rosuvastatin calcium tablets therapy with 5 mg once daily. The dose of rosuvastatin calcium tablets should not exceed 10 mg once daily [see Warnings and Precautions (5.1), Drug Interactions (7.3) and Clinical Pharmacology (12.3)]

2.5 Dosing in Patients with Severe Renal Impairment For patients with severe renal impairment (CL $_{\rm er}$ <30 mL/min/1.73 m²) not on hemodialysis, dosing of rosuvastatin calcium tablets should be started at 5 mg once daily and not exceed 10 mg once daily [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

5 mg tablets: Yellow colored, circular, biconvex, film-coated tablets with 'S' debossed on one side and plain on the other side of the tablet

10 mg tablets: Pink colored, circular, biconvex, film-coated tablets with '583' debossed on one side and plain on the other side of the table


Abdominal pain 2.4 1.8 $ALT > 3x ULN^2$ 2.2 0.7 Adverse reactions by MedDRA preferred term. Frequency recorded as abnormal laboratory value

In a clinical trial, 17,802 participants were treated with rosuvastatin 20 mg (n=8,901) or placebo (n=8,901) for a mean duration of 2 years. A higher percentage of rosuvastatin-treated patients versus placebo-treated patients. 6.6% and 6.2%, respectively, discontinued study medication due to an adverse event, irrespective of treatment causality. Myalgia was the most common adverse reaction that led to treatment discontinuation.

There was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1c > 6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated patients [see Warnings and Precautions (5.6)

Adverse reactions reported in \ge 2% of patients and at a rate greater than placebo are shown in Table 3.

Table 3. Adverse Reactions' Reported in ≥2% of Patients Treated with Rosuvastatin and > Placebo in a Trial (% of Patients)



Treatment-emergent adverse reactions by MedDRA preferred term.

6.2 Postmarketing Experience

lowing adverse reactions have been identified during postapproval use of rosuvastatin: arthralgia, fatal and non-fatal hepatic failure, hepatitis, jaundice, thrombocytopenia, depression, sleep disorders (including insomnia and nightmares), peripheral neuropathy, interstitial long disease and gynecomastia. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see Warnings and Precautions (5.2)].

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with statu use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to mptom onset (1 day to years) and symptom resolution (median of 3 weeks).

DRUG INTERACTIONS

71 Cyclosporine Cyclosporine increased rosuvastatin exposure and may result in increased risk of myopathy. Therefore, in patients taking cyclosporine, the dose of rosuvastatin should not exceed 5 mg once daily [see Dosage and stration (2.4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

7.2 Gemfibrozi Gemfibrozil significantly increased rosuvastatin exposure. Due to an observed increased risk of nyopathy/rhabdomyolysis, combination therapy with rosuvastatin and gemfibrozil should be avoided. If used

ogether, the dose of rosuvastatin should not exceed 10 mg once daily [see Clinical Pharmacology (12.3)]. 7.3 Anti-viral Medications

Coadministration of rosuvastatin with certain anti-viral drugs have differing effects on rosuvastatin exposure and may increase risk of myopathy.

The combination of sofosbuvir/velpatasvir/voxilaprevir which are anti-Hepatitis C virus (anti-HCV) drugs, increases rosuvastatin exposure. Similarly, the combination of ledipasvir/sofosbuvir may significantly increase rosuvastatin exposure. For these combinations of anti-HCV drugs, concomitant use with rosuvastatin is not recommended.

Simeprevir and combinations of dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvi velpatasvir and glecaprevir/pibrentasvir which are anti-HCV drugs, increase rosuvastatin exposure. Combinations of atazanavir/ritonavir and lopinavir/ritonavir, which are anti-HIV-1 drugs, increase rosuvastatin exposure [see Table 4 - Clinical Pharmacology (12.3)]. For these anti-viral drugs, the dose of rosuvastatin ould not exceed 10 mg once daily.

The combinations of fosamprenavir/ritonavir or tipranavir/ritonavir, which are anti-HIV-1 drugs, produce little or no change in rosuvastatin exposure. No dose adjustment is needed for concomitant use with these combinations [see Dosage and Administration (2.4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

7.4 Darolutamide

rolutamide increased rosuvastatin exposure more than 5 fold. Therefore, in patients taking darolutamide, the dose of rosuvastatin should not exceed 5 mg once daily [see Dosage and Administration (2.4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

7.5 Regorafenib

Regoratenib increased rosuvastatin exposure and may increase the risk of myopathy. If used together, the dose of suvastatin should not exceed 10 mg once daily [see Dosage and Administration (2.4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]

7.6 Coumarin Anticoagulants

Rosuvastatin significantly increased INR in patients receiving cournarin anticoagulants. Therefore, caution should be exercised when coumarin anticoagulants are given in conjunction with rosuvastatin. In patients taking coumarin anticoagulants and rosuvastatin concomitantly. INR should be determined before starting rosuvastatin and frequently enough during early therapy to ensure that no significant alteration of INR occurs [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].

The risk of skeletal muscle effects may be enhanced when rosuvastatin is used in combination with lipid-

nodifying doses (\geq 1 g/day) of niacin; caution should be used when prescribing with rosuvastatin [see Warnings and Precautions (5.1)].

Caution should be exercised when anticcagulants are given in conjunction with rosuvastatin because of its potentiation of the effect of coumarin-type anticcagulants in prolonging the prothrombin time/INR. In patients 7.8 Fenofibrate

7.7


When rosuvastatin was coadministered with fenofibrate, no clinically significant increase in the AUC of statin or fenofibrate was observed. Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should be used when rescribing fenofibrates with rosuvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology 8.7 Hepatic Impairment Rosuvastatin is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels. Chronic alcohol liver disease is known to increase rosuvastatin statin should be used with caution in these patients [see Contraindications (4), Warning and

Precautions (5.3) and Clinical Pharmacology (12.3)]. 8.8 Asian Patients Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin In Asian subjects when compared with Caucasian controls. Rosuvastatin dosage hould be adjusted in Asian patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

10 OVERDOSAGE There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis does not significantly enhance clearance of rosuvastati

11 DESCRIPTION Rosuvastatin calcium is a synthetic lipid-lowering agent for oral administration.

The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:



The molecular formula for rosuvastatin calcium is $(C_{22}H_{27}FN_3O_8S)_2$ •Ca and the molecular weight is 1001.14. Rosuvastatin calcium USP is a white to off-white amorphous powder that is slightly soluble in water, and practically insoluble in ethanol and methanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0.

Rosuvastatin calcium tablets for oral administration contain 5 mg, 10 mg, 20 mg, or 40 mg of rosuvastatin and the following inactive ingredients: colloidal silicon dioxide, hyporenellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg).

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. In vivo studies in animals, and *in vitro* studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for cholesterol lowering. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.

12.2 Pharmacodynamics

Rosuvastatin dose dependently reduces elevated LDL-cholesterol and reduces total cholesterol and triglycerides and increases HDL-cholesterol [see *Clinical Studies* (14)]. A therapeutic response to rosuvastatin is evident within 1 week of commencing therapy and 90% of maximum response is usually achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that. Individualization of drug dosage should be based on the therapeutic response [see Dosage and Administration (2)]

12.3 Pharmacokinetics Absorption

n clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both C_{max} and AUC increased in approximate proportion to rosuvastatin dose. The absolute bioavailability of rosuvastatin is approximately 20%.

Administration of rosuvastatin with food did not affect the AUC of rosuvastatin

The AUC of rosuvastatin does not differ following evening or morning drug administration.

Distributio Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma co

Rosuvastatin is primarily eliminated by excretion in the feces. The elimination half-life of rosuvastatin is

Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound

Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.

Specific Population

Racial or Ethnic Groups

populations (age \geq 65 years).

A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among A population pharmaconnect analysis revealed in clinically reveal of metarrows in pharmaconnectors and grant and gr Asian subjects when compared with a Caucasian control group

Male and Female Patients There were no differences in plasma concentrations of rosuvastatin between men and womer

Pediatric use information for patients ages 8 to less than 10 years is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information

Geriatric Patients There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly

KLD_OPEN SIZE: 570 MM X380 MM / CLOSE SIZE : 35X34 MM 11/05/2018

570 SIDE

FRONT

neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Consider risk of IMNM carefully prior to initiation of a different statin. If therapy is initiated with a different

It is recommended that liver enzyme tests be performed before the initiation of rosuvastatin, and if signs or

Increases in serum transaminases [AST (SGOT) or ALT (SGPT)] have been reported with HMG-CoA reductase

inhibitors, including rosuvastatin. In most cases, the elevations were transient and resolved or improved on

continued therapy or after a brief interruption in therapy. There were two cases of jaundice, for which a relationship to rosuvastatin therapy could not be determined, which resolved after discontinuation of therapy.

In a pooled analysis of placebo-controlled trials, increases in serum transaminases to >3 times the upper limit of

There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins,

including rosuvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with rosuvastatin, promptly interrupt therapy. If an alternate etiology is not found, do not restart

Rosuvastatin should be used with caution in patients who consume substantial quantities of alcohol and/or have a

history of chronic liver disease [see Clinical Pharmacology (12.3)]. Active liver disease, which may include

unexplained persistent transaminase elevations, is a contraindication to the use of rosuvastatin [see

taking coumarin anticoagulants and rosuvastatin concomitantly. INR should be determined before starting

statin and frequently enough during early therapy to ensure that no significant alteration of INR occurs [see

normal occurred in 1.1% of patients taking rosuvastatin versus 0.5% of patients treated with placebo

There were no cases of liver failure or irreversible liver disease in these trials.

1

statin, monitor for signs and symptoms of IMNM.

5.3 Liver Enzyme Abnormalities

symptoms of liver injury occur.

Contraindications (4)].

Drug Interactions (7.6)].

5.4 Concomitant Coumarin Anticoagulants



						3	<u>380</u> 35 mm	_	
	157.5 n	mm				•		18	7.5 mm
Patients with Renal Impairment Mild to moderate renal impairment ($CL_{\alpha} > 30 \text{ mL/min}/1.73 \text{ m}^2$) had rosuvastatin. However, plasma concentrations of rosuvastatin increas fold) in patients with severe renal impairment ($CL_{\alpha} < 30 \text{ mL/min}/1.73 \text{ with healthy subjects (CL_{\alpha} > 80 \text{ mL/min}/1.73 \text{ m}^2).$	ed to a clinically significant (nt extent (about 3-		eridemia <i>Idy:</i> In a double-blind, 817 mg/dL, rosuvast	I, placebo-controlled dose-res statin given as a single daily he 9).			How should I take rosuvastatin calcium tablets? • Take rosuvastatin calcium tablets exactly as your doctor tells you to take it. • Take rosuvastatin calcium tablets, by mouth, 1 time each day. Swallow the tablet whole. • Rosuvastatin calcium tablets can be taken at any time of day. with or withour food. • Do not change your dose or stop rosuvastatin calcium tablets withoout taking to your doctor, even	iiiiii
<i>Hemodialysis</i> Steady-state plasma concentrations of rosuvastatin in patients on chro		oproximately 50%	Table	e 9. Dose-Response i	in Patients with Primary Hy dian (Min, Max) Percent Cha			 if you are feeling well. Your doctor may do blood tests to check your cholesterol levels before and during your treatment with rosuvastatin calcium tablets. Your doctor may change your dose of rosuvastatin calcium 	
greater compared with healthy volunteer subjects with normal renal fur Patients with Hepatic Impairment	ction.			Placebo Rosi	suvastatin Rosuvastatin	Rosuvastatin	Rosuvastatin	tablets if needed. Your doctor may start you on a cholesterol lowering diet before giving you rosuvastatin calcium 	
In patients with chronic alcohol liver disease, plasma concentrations of		-	Dose	(n=26) (r	5 mg 10 mg (n=25) (n=23)	20 mg (n=27)	40 mg (n=25)	 tablets. Stay on this diet when you take rosuvastatin calcium tablets. Wait at least 2 hours after taking rosuvastatin calcium tablets to take an antacid that contains a combination of aluminum and magnesium hydroxide. 	
In patients with Child-Pugh A disease, C _{max} and AUC were increased b with patients with normal liver function. In patients with Child-Pugh B d and 21%, respectively, compared with patients with normal liver function	isease, C_{max} and AUC were in				(-58, 38) -37 (-65, 5) 9 (-43, -8) -49 (-59, -20)	-37 (-72, 11) -43 (-74, 12)	-43 (-80, -7) -51 (-62, -6)	 If you miss a dose of rosuvastatin calcium tablets, take it as soon as you remember. However, do not take 2 doses of rosuvastatin calcium tablets within 12 hours of each other. 	
Drug Interactions Studies			VLDL-C	2 (-36, 53) -25	6 (-62, 49) -48 (-72, 14)	-49 (-83, 20)	-56 (-83, 10)	 If you take too many rosuvastatin calcium tablets or overdose, call your doctor or go to the nearest hospital emergency room right away. 	
Rosuvastatin clearance is not dependent on metabolism by cytoch extent.	rome P450 3A4 to a clinic	nically significant			4 (-40, -4) -40 (-51, -14) 8 (-71, 2) -45 (-59, 7)	-34 (-61, -11) -31 (-66, 34)	-40 (-51, -4) -43 (-61, -3)	What are the Possible Side Effects of Rosuvastatin Calcium Tablets?	
Rosuvastatin is a substrate for certain transporter proteins includir anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter Concomitant administration of rosuvastatin with medications that are in cyclosporine, certain HIV protease inhibitors) may result in increased Dosage and Administration (2.4) and Drug Interactions (7.1, 7.3)]. Table 4. Effect of Coadministered Drugs on Rosuva	breast cancer resistance p hibitors of these transporte rosuvastatin plasma conc	e protein (BCRP). rter proteins (e.g. ncentrations <i>[see</i>	14.4 Primary Dysl In a randomized, muli [Arg145Cys] with	betalipoproteinemia Iticenter, double-blind primary dysbeta	(-38, 33) 8 (-8, 24) a (Type III Hyperlipoproteiner d crossover study, 32 patients alipoproteinemia (Type III	(27 with c2/c2 and 4 Hyperlipoprotein	inemia) entered a	Rosuvastatin calcium tablets may cause serious side effects, including: Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your doctor right away if: o you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take rosuvastatin calcium tablets. o you have muscle problems that do not go away even after your doctor has told you to stop table are caused in the action.	
Coadministered drug and dosing regimen	Rosuvastatin		patients were randor	mized to a sequence	EP Therapeutic Lifestyle Chan e of treatments in conjunctio statin 20 mg or rosuvastatin 2	n with the TLC die	et for 6 weeks each:	taking rosuvastatin calcium tablets. Your doctor may do further tests to diagnose the cause of your muscle problems. Your chances of getting muscle problems are higher if you:	
	Mean Ratio (ratio wi			ed non HDL-C (primar	ary end point) and circulating			 are taking certain other medicines while you take rosuvastatin calcium tablets are 65 years of age or older 	
Dose (mg)'	coadministered drug) N Change in AUC Ch	No Effect=1.0 Change in C _{max}			Effects of Rosuvastatin 10 n (Type III hyperlipoproteinem			 have thyroid problems (hypothyroidism) that are not controlled have kidney problems are taking higher doses of rosuvastatin calcium tablets 	
Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (400 mg-100 mg) case delta for 15 days	7.39 ² (6.68 to 8.18) ³ (16.	18.88 ² 6.23 to 21.96) ³	Dysu		nt Change (95% CI) from Bas	eline (N=32)		 Liver problems. Your doctor should do blood tests to check your liver before you start taking rosuvastatin calcium tablets and if you have symptoms of liver problems while you take 	
Cyclosporine - stable dose required (75 mg to 200 mg BID) 10 mg QD for 10 days	7.12	11 ²		Median at Baseline (mg/d		fro	i percent change om baseline (95% CI) vastatin 20 mg	rosuvastatin calcium tablets. Call your doctor right away if you have any of the following symptoms of liver problems: o feel unusually tired or weak o loss of appetite	
Darolutamide 600 mg BID, 5 days 5 mg, single dose	5.2 ²	~5²	Total-C	342.5 503.5	-43.3 (-46.9, -37.5	,	6 (-51.6,-42.8)	o upper belly pain o dark urine	
Regorafenib 160mg OD, 14 days 5 mg, single dose	3.8 ²	4.6 ²	Triglycerides NonHDL-C	294.5	-48.2 (-56.7, -45.6	,	(-52.5, -33.1) (-61.4, -48.5)	o yellowing of your skin or the whites of your eyes	
Atazanavir/ritonavir combination 10 mg 300 mg/100 mg QD for 8 days	3.1 ²	7 ²	VLDL-C + IDL-C LDL-C		-46.8 (-53.7, -39.4	4) -56.2	2 (-67.7, -43.7)		
	2.8^2	3.2^2 (2.6 to 3.9) ³		1125	-54 4 (-59 1 -47	3) -57.3	(-59.4 -52.1)	The most common side effects may include: headache, muscle aches and pains, abdominal pain, weakness, and nausea. Additional side effects that have been reported with resuvastatin calcium tablets include memory loss	
Simeprevir 150 mg QD, 7 days 10 mg, single dose	, , ,	0.042	HDL-C	112.5 35.5	-54.4 (-59.1, -47.3	-	8 (-59.4, -52.1) 2 (8.3, 20.5)		
Velpatasvir 100 mg once daily single dose single dose	$\begin{array}{c} 2.69^2 \\ (2.46 \text{ to } 2.94)^3 \end{array} (2.$	2.61^{2} (2.32 to 2.92) ³	HDL-C RLP-C	35.5 82.0	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0	11.2 0) -64.9	2 (8.3, 20.5) 0 (-74.0, -56.6)	weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist.	
Simeprevir 150 mg dub, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose	$\begin{array}{c} 2.69^2 \\ (2.46 \text{ to } 2.94)^3 \\ 2.59^2 \\ (2.09 \text{ to } 3.21)^3 \end{array} (5.5)^2 \\ \end{array}$	(2.32 to 2.92) ³ 7.13 ² (5.11 to 9.96) ³	HDL-C	35.5	10.2 (1.9, 12.3)	11.2 0) -64.9	2 (8.3, 20.5)	weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your	
Simplevir 150 mg db, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose	$\begin{array}{c} 2.69^2 \\ (2.46 \text{ to } 2.94)^3 \\ (2.59^2 \\ (2.09 \text{ to } 3.21)^3 \\ (5.226^2 \\ (1.89 \text{ to } 2.69)^3 \\ (4.36 \text{ to } 2.69)^3 \\ \end{array}$	$ \begin{array}{r} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^2 \\ (4.29 \text{ to } 7.04)^3 \end{array} $	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-label	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0 -42.9 (-46.3, -33.3 esterolemia el, forced-titration study, ho	11.2 0) -64.9 3) -42.5 pmozygous FH pat	2 (8.3, 20.5) (-74.0, -56.6) (-47.1, -35.6) attients (n=40, 8 to	weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets?	
Simplevit 150 mg db, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 5 mg, single dose Ibasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \mbox{ to } 2.94)^{\circ} \\ (2.09 \mbox{ to } 3.21)^{\circ} \\ (2.2.6^{\circ} \\ (1.89 \mbox{ to } 2.69)^{\circ} \\ (1.89 \mbox{ to } 2.69)^{\circ} \\ (1.88 \mbox{ to } 2.60)^{\circ} \\ (1.88 \mbox{ to } 2.60)^{\circ} \\ (4.88 \mbox{ to } 2.46)^{\circ} \\ (4.88$	$\frac{(2.32 \text{ to } 2.92)^3}{7.13^2}$ $\frac{(5.11 \text{ to } 9.96)^3}{5.49^2}$ $\frac{(4.29 \text{ to } 7.04)^3}{5.62^2}$ $\frac{(4.80 \text{ to } 6.59)^3}{6.59}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th	35.5 82.0 16.0 s Familial Hyperchole dy: in an open-labe juated for their respons emean LDL-C reduct	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.3) esterolemia el, forced-titration study, hc use to rosuvastatin 20 mg to 4 tion from baseline was 22%	11.2 0) -64.9 3) -42.5 omozygous FH pat 0 mg titrated at a 6- About one-third of t	2 (8.3, 20.5) (-74.0, -56.6) (-74.1, -35.6) titients (n=40, 8 to 5-week interval. In the the patients benefited	weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? • Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. • Safely throw away medicine that is out of date or no longer needed.	
Simplevit 150 mg db, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 5 mg, single dose I00 mg + dasabuvir 400 mg BID single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once 5 mg once daily	$\begin{array}{c} 2.69^{2} \\ (2.46 \ to \ 2.94)^{3} \\ (2.59^{2} \\ (2.09 \ to \ 3.21)^{3} \\ (5.26^{2} \\ (1.89 \ to \ 2.69)^{3} \\ (4.215^{2} \\ (1.88 \ to \ 2.46)^{3} \\ (4.215^{2} \\ (1.88 \ to \ 2.46)^{3} \\ (4.215^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (5.215^{2} \\ (4.215^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (5.215^{2} \\ (4.215^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (5.215^{2} \\ (4.215^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (5.215^{2} \\ (4.215^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (5.215^{2} \\ (5.215^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (1.7 \ to \ 2.6)^{$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 5^2 \\ (3.4 \text{ to } 6.4)^2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL-	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-labe lated for their respons ne mean LDL-C reduct dose from 20 mg to 4 douction in LDL-C, the C reduction of <15%,	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, hcd use to rosuvastatin 20 mg to 4 titon from baseline was 22%. 40 mg with further LDL lower e mean LDL-C reduction was 32 6, 3 had no change or an increa	11.2 0) -64.9 3) -42.5 omg titrated at a 6 About one-third of t ing of greater than 6 30% (median 28% ref se in LDL-C. Reduct	2 (8.3, 20.5) (-74.0, -56.6) i (-47.1, -35.6) attients (n=40, 8 to 6-week interval. In the the patients benefited 6%. In the 27 patients reduction). Among 13	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. 	
Simeprevir 130 mg db, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 20 mg QD for	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \mbox{ to } 2.94)^{\circ} \\ (2.59^{\circ} \\ (2.09 \mbox{ to } 3.21)^{\circ} \\ (2.09 \mbox{ to } 3.21)^{\circ} \\ (1.89 \mbox{ to } 2.69)^{\circ} \\ (1.89 \mbox{ to } 2.69)^{\circ} \\ (4.8 \mbox{ to } 2.46)^{\circ} \\ (4.8 \mbox{ to } 2.6)^{\circ} \\ (1.7 \mbox{ to } 2.6)^{\circ} \\ (1.7 \mbox{ to } 2.6)^{\circ} \\ (1.6 \mbox{ to } 2.6)^{\circ} \\ (1.6 \mbox{ to } 2.2)^{\circ} \\ (1.6 \mbox{ to } $	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 5^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^3 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL-	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-labe lated for their respons ne mean LDL-C reduct dose from 20 mg to 4 douction in LDL-C, the C reduction of <15%,	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, he isse to rosuvastatin 20 mg to 4 40 mg with further LDL lower e mean LDL-C reduction was 28%.	11.2 0) -64.9 3) -42.5 omg titrated at a 6 About one-third of t ing of greater than 6 30% (median 28% ref se in LDL-C. Reduct	2 (8.3, 20.5) (-74.0, -56.6) i (-47.1, -35.6) attients (n=40, 8 to 6-week interval. In the the patients benefited 6%. In the 27 patients reduction). Among 13	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredient: rosuvastatin as rosuvastatin calcium Inactive Ingredient: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline 	
Simplevit 150 mg dD, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 5 mg, single dose 100 mg + dasabuvir 400 mg BID single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 20 mg QD for 7 days Gemfibrozil 600 mg BID for 7 days 80 mg Eltrombopag 75 mg QD, 5 days 10 mg	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ {\rm to} \ 2.94)^{\circ} \\ (2.90 \ {\rm to} \ 3.21)^{\circ} \\ (2.90 \ {\rm to} \ 3.21)^{\circ} \\ (5.90 \ {\rm to} \ 3.21)^{\circ} \\ (1.89 \ {\rm to} \ 2.69)^{\circ} \\ (4.9 \ {\rm to} \ 2.69)^{\circ} \\ (5.9 \ {\rm to} \ 2.69)^{\circ} \\ (6.9 \ {\rm to} \ 2.9)^{\circ} \\ (7.9 \ {\rm to} \ 2.9)^{\circ} \\ (1.6 \ {\rm to} \ 2.29)^{\circ} \\ (1.6 \ {\rm to} \ 2.19)^{\circ} \ (1.6 \ {\rm$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 5^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2 \\ (1.8 \text{ to } 2.3)^2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform (rosuvastatin calciu	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-label uated for their respons re mean LDL-C reduct r dose from 20 mg to duction dose from 20 mg to duction dose from 20 mg to duction r dose from 20 mg to duction r do	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, hcd usse to rosuvastatin 20 mg to 4 ytion from baseline was 22%. 40 mg with further LDL lower mean LDL-C reduction was 5 5, 3 had no change or an increa with known receptor negative st to 17 years of age is approv r, due to AstraZeneca's mark	11.2 D) -64.9 3) -42.5 D) 0 mg titrated at a 6- About one-third of t ing of greater than 6 30% (median 28% re se in LDL-C. Reduct status.	2 (8.3, 20.5) 9 (-74.0, -56.6) 6 (-47.1, -35.6) attients (n=40, 8 to 5-week interval. In the the patients benefited 6%. In the 27 patients reduction). Among 13 tions in LDL-C of 15% ca's CRESTOR	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin calcium Inactive Ingredient: cosloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 	
Simeprevir 130 mg db, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg QD for 7 days Gemfibrozil 600 mg BID for 7 days 80 mg	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ {\rm to} \ 2.94)^{\circ} \\ (2.09 \ {\rm to} \ 3.21)^{\circ} \\ (2.09 \ {\rm to} \ 3.21)^{\circ} \\ (1.89 \ {\rm to} \ 2.69)^{\circ} \\ (1.89 \ {\rm to} \ 2.69)^{\circ} \\ (1.88 \ {\rm to} \ 2.60)^{\circ} \\ (1.88 \ {\rm to} \ 2.60)^{\circ} \\ (1.7 \ {\rm to} \ 2.6)^{\circ} \\ (1.7 \ {\rm to} \ 2.6)^{\circ} \\ (1.7 \ {\rm to} \ 2.6)^{\circ} \\ (1.6 \ {\rm to} \ 2.2)^{\circ} \\ (1.6 \ {\rm to} \ 2.2)^{\circ} \\ (1.6 \ {\rm to} \ 2.2)^{\circ} \\ (1.5 \ {\rm to} \ 2.1)^{\circ} \ (1.5 \ {\rm to} \ $	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 5^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^2 \\ \hline 2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-label uated for their respons re mean LDL-C reduct r dose from 20 mg to duction dose from 20 mg to duction dose from 20 mg to duction r dose from 20 mg to duction r do	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, hcd usse to rosuvastatin 20 mg to 4 ytion from baseline was 22%. 40 mg with further LDL lower mean LDL-C reduction was 5 5, 3 had no change or an increa with known receptor negative st to 17 years of age is approv r, due to AstraZeneca's mark	11.2 D) -64.9 3) -42.5 D) 0 mg titrated at a 6- About one-third of t ing of greater than 6 30% (median 28% re se in LDL-C. Reduct status.	2 (8.3, 20.5) 9 (-74.0, -56.6) 6 (-47.1, -35.6) attients (n=40, 8 to 5-week interval. In the the patients benefited 6%. In the 27 patients reduction). Among 13 tions in LDL-C of 15% ca's CRESTOR	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredient: rosuvastatin a srosuvastatin calcium Inactive ingredient: rosuvastatin calcium disvide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg). 	
Simplevir 150 mg dD, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg QD for 7 days Gemfibrozil 600 mg BID for 7 days 80 mg Eltrombopag 75 mg QD, 5 days 10 mg Darunavir 600 mg/ritonavir 100 mg BID, 10 mg QD for 7	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ to \ 2.94)^3 \\ (2.09 \ to \ 3.21)^3 \\ (2.09 \ to \ 3.21)^3 \\ (5.26^{\circ} \\ (1.89 \ to \ 2.69)^3 \\ (4.2.15^{\circ} \\ (1.88 \ to \ 2.46)^3 \\ (4.2.15^{\circ} \\ (1.7 \ to \ 2.6)^3 \\ (1.7 \ to \ 2.6)^3 \\ (1.6 \ to \ 2.2)^3 \\ (1.6 \ to \ 2.2)^3 \\ (1.6 \ to \ 2.2)^3 \\ (1.6 \ (1.4 \ to \ 1.7)^3 \\ (1.5 \ (1.0 \ to \ 2.1)^3 \\ (1.4 \ to \ 1.7)^3 \\ (1.4 \ to \$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^3 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 6^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2 \\ (1.8 \text{ to } 2.3)^3 \\ \hline 2.4 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform (rosuvastatin calciu) product is not labele	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-labe ated for their respons ne mean LDL-C reduct dose from 20 mg to 4 douction in LDL-C, the C reduction of LDL-C, the C reduction of < 15%, rved in 3 of 5 patients v nation for patients 7 f im) tablets. However, ed with that pediatric	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, ho isse to rosuvastatin 20 mg to 4 tition from baseline was 22%. 40 mg with further LDL lower meman LDL-C reduction was 3 6, 3 had no change or an increa with known receptor negative is to 17 years of age is approvir, due to AstraZeneca's marking ic information.	11.2 D) -64.9 3) -42.5 D) -64.9 3) -42.5 D) -42.5 D) 0 mg titrated at a 6 About one-third of t 1 ing of greater than 6 30% (median 28% re 00% (median 28% re 1 00% (median 28% re 1 se in LDL-C. Reduct status. 1 ved for AstraZenec: 1 veting exclusivity ri 1	2 (8.3, 20.5) 0 (-74.0, -56.6) 6 (-47.1, -35.6) Attients (n=40, 8 to 5-week interval. In the the patients benefited 6%. In the 27 patients reduction). Among 13 titions in LDL-C of 15% ca's CRESTOR rights, this drug	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin calcium Inactive Ingredient: cosloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 	
Sinteprevir 150 mg (db, 7 days) single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg QD for 7 days Gemfibrozil 600 mg BID for 7 days 80 mg Eltrombopag 75 mg QD, 5 days 10 mg Darunavir 600 mg/ritonavir 100 mg BID, 7 days 10 mg QD for 7 days Tipranavir/ritonavir combination 10 mg	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ to \ 2.94)^3 \\ (2.59^{\circ} \\ (2.09 \ to \ 3.21)^3 \\ (5.26^{\circ} \\ (1.89 \ to \ 2.69)^3 \\ (4.2.15^{\circ} \\ (1.88 \ to \ 2.46)^3 \\ (4.2.15^{\circ} \\ (1.88 \ to \ 2.46)^3 \\ (4.2.15^{\circ} \\ (1.78 \ to \ 2.6)^3 \\ (1.6 \ to \ 2.2)^3 \\ (1.6 \ to \ 2.2)^3 \\ (1.6 \ to \ 2.2)^3 \\ (1.6 \ to \ 2.1)^3 \\ (1.5 \ (1.16 \ 1.7)^3 \\ (1.2 \ to \ 1.6)^3 \\ (1.2 \ to \ 1.6)^3 \\ (1.4 \ (1.2 \ to \ 1.6)^3 \\ (1.4 \ (1.2 \ to \ 1.6)^3 \\ (1.4 \ (1.4 \ to \ 1.7)^3 \\ (1.4 \ (1.4 \ to \ 1.7)^3 \\ (1.4 \ (1.4 \ to \ 1.6)^3 \\ (1$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.69^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 6^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2 \\ (1.8 \text{ to } 2.3)^3 \\ \hline 2.4 \\ (1.6 \text{ to } 3.6)^3 \\ \hline 2.2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2.4 \\ (1.6 \text{ to } 3.6)^2 \\ \hline 2.2 \\ (1.8 \text{ to } 2.7)^3 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform (rosuvastatin calcium product is not labelet 16 HOW SUPPLI Rosuvastatin calcium 5 mg tablets: Yellow c	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-label uated for their respons re mean LDL-C reduct r dose from 20 mg to 4 douction in LDL-C, the -C reduction of < 15%, rved in 3 of 5 patients v mation for patients 7 f mm) tablets. However, ed with that pediatric IED/STORAGE AND H n tablets are available of colored, circular, bicor	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, hcd use to rosuvastatin 20 mg to 4 tition from baseline was 22%. 40 mg with further LDL lower e mean LDL-C reduction was 2 5, 3 had no change or an increa with known receptor negative : to 17 years of age is approv r, due to AstraZeneca's mark ic information.	11.2 D) -64.9 3) -42.5 D) 0 mg titrated at a 6- About one-third of t 1 ing of greater than 6 60% (median 28% rr se in LDL-C. Reduct status. ved for AstraZenec: veting exclusivity ri g or 40 mg of rosuva g or 40 mg of rosuva	2 (8.3, 20.5) 0 (-74.0, -56.6) i (-47.1, -35.6) attients (n=40, 8 to 6-week interval. In the the patients benefited 6%. In the 27 patients reduction). Among 13 reduction, Among 13 reduction, Among 14 tions in LDL-C of 15% ca's CRESTOR rights, this drug Pastatin.	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredient: rosuvastatin as rosuvastatin calcium Inactive Ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg). General Information about the safe and effective use of rosuvastatin calcium tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets to other people, even if they have the same medical condition you have. It may harm them. 	
Simplevit 150 mg dD, 7 dayssingle doseVelpatasvir 100 mg once daily10 mg, single doseOmbitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID5 mg, single doseElbasvir 50 mg/grazoprevir 200 mg once daily Glecaprevir 400 mg/pibrentasvir 120 mg once daily5 mg once daily comg QD for 7 daysLopinavir/ritonavir combination 400 mg/100 mg BID for 7 days20 mg QD for 7 daysGemfibrozil 600 mg BID for 7 days10 mg 20 mg QD for 7 daysDarunavir 600 mg/ritonavir 100 mg BID, 7 days10 mg QD for 7 daysTipranavir/ritonavir combination 500 mg/200mg BID for 11 days10 mg	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ to \ 2.94)^3 \\ (2.59^{\circ} \\ (2.09 \ to \ 3.21)^3 \\ (2.26^{\circ} \\ (1.89 \ to \ 2.69)^3 \\ (4.2.15^{\circ} \\ (1.88 \ to \ 2.46)^3 \\ (4.2.15^{\circ} \\ (1.78 \ to \ 2.69)^3 \\ (4.2.15^{\circ} \\ (1.78 \ to \ 2.69)^3 \\ (4.2.15^{\circ} \\ (1.78 \ to \ 2.69)^3 \\ (1.6 \ to \ 2.29)^3 \\ (1.6 \ to \ 2.21)^3 \\ (1.6 $	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.69^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 5^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^2 \\ \hline 2 \\ (1.8 \text{ to } 2.3)^3 \\ \hline 2.4 \\ (1.6 \text{ to } 3.6)^3 \\ \hline 2.2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud G3 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform (rosuvastatin calciu product is not labele 16 HOW SUPPLI Rosuvastatin calcium 5 mg tablets: Yellow c other side of the table! Bottles of 90 with chil 10 mg tablets: Pink c	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-labe ated for their respons ne mean LDL-C reduct dose from 20 mg to 4 douctoin in LDL-C, the C reduction of the their state in the their state state attraction of the their state minimum state state state attraction of the their state	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, hcl ses to rosuvastatin 20 mg to 4 tition from baseline was 22%. 40 mg with further LDL lower e mean LDL-C reduction was 32 6, 3 had no change or an increa with known receptor negative : to 17 years of age is approver, due to AstraZeneca's mark ic information. HANDLING containing 5 mg, 10 mg, 20 m onvex, film-coated tablets with	11.2 D) -64.9 3) -42.5 D) -64.9 3) -42.5 D) -64.9 0 mg titrated at a 6- About one-third oft ing of greater than 6 00% (median 28% re se in LDL-C. Reduct status. red for AstraZenec: teting exclusivity ri g or 40 mg of rosuva 'S' debossed on one	2 (8.3, 20.5) 0 (-74.0, -56.6) 0 (-74.0, -56.6) 4 (-47.1, -35.6) 4 (-47.1, -37.6) 4 (-47.1, -37.6	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin calcium Ingredient: rosuvastatin calcium fablets? Active Ingredient: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg). General Information about the safe and effective use of rosuvastatin calcium tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin calcium tablets or a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets or a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets or a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets ot other people, even if they have the same medical condition you have. It 	
Sinteprevir 150 mg (db, 7 days) single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 5 mg, single dose 100 mg + dasabuvir 400 mg BID single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 20 mg QD for 7 days Gemfibrozil 600 mg BID for 17 days 80 mg Eltrombopag 75 mg QD, 5 days 10 mg QD for 7 days Tipranavir/ritonavir combination 10 mg QD for 7 days Tipranavir/ritonavir combination 10 mg 500 mg/200mg BID for 11 days 10 mg Dronedarone 400 mg BID 10 mg Itraeoegrapic 200 mg OD 5 days 10 mg	$\begin{array}{c} 2.69^{2} \\ (2.46 \ to \ 2.94)^{3} \\ (2.59^{2} \\ (2.09 \ to \ 3.21)^{3} \\ (5.26^{2} \\ (1.89 \ to \ 2.69)^{3} \\ (4.2.15^{2} \\ (1.88 \ to \ 2.46)^{3} \\ (4.2.15^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (1.6 \ to \ 2.2)^{2} \\ (1.6 \ to \ 2.2)^{3} \\ (1.6 \ to \ 2.2)^{3} \\ (1.6 \ to \ 2.1)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.4 \ to \ 1.6)^{3} \\ (1.4 \ to \ 1.6)^{3} \\ (1.4 \ to \ 1.6)^{3} \\ (1.1 \ to \ 1.4)^{3} \\ (1.1 \ to \ 1.4)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.2 \ to \ 1$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 0.96)^3 \\ \hline 5.69^2 \\ (4.29 0 7.04)^3 \\ \hline 5.62^2 \\ (4.80 to 6.59)^3 \\ \hline 5^2 \\ (3.4 to 6.4)^3 \\ \hline 2.2^2 \\ (1.8 to 2.7)^3 \\ \hline 2 \\ (1.8 to 2.3)^3 \\ \hline 2.4 \\ (1.6 to 3.6)^3 \\ \hline 2.2 \\ (1.8 to 2.7)^3 \\ \hline 1.4 \\ (1.2 to 1.5)^3 \\ \hline 1.2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform (rosuvastatin calciu product is not labele 16 HOW SUPPLI Rosuvastatin calcium 5 mg tablets: Yellow co other side of the tablet Bottles of 90 with chil	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-labe uated for their respons re mean LDL-C reduct dose from 20 mg to 4 eduction in LDL-C, the C reduction of <15%, rved in 3 of 5 patients v nation for patients 7 im) tablets. However, ed with that pediatric LIED/STORAGE AND H n tablets are available of colored, circular, bicon t.	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, hotose to rosuvastatin 20 mg to 4 ytion from baseline was 22%. 40 mg with further LDL lower mean LDL-C reduction was 3 6, 3 had no change or an increa with known receptor negative structure information. to 17 years of age is approximate information. HANDLING containing 5 mg, 10 mg, 20 m onvex, film-coated tablets with	11.2 D) -64.9 3) -42.5 Domozygous FH pather 0 mg titrated at a 6- About one-third oft ing of greater than 6 30% (median 28% rd se in LDL-C. Reduct status. red for AstraZenec: reting exclusivity ri g or 40 mg of rosuva 'S' debossed on one '583' debossed on of	2 (8.3, 20.5) 0 (-74.0, -56.6) 0 (-74.0, -56.6) 4 (-47.1, -35.6) 4 (-47.1, -37.6) 4 (-47.1, -37.6	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredient: rosuvastatin as rosuvastatin calcium Inactive Ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, taic, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg). General Information about the safe and effective use of rosuvastatin calcium tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin calcium tablets for a condition for which it was not prescribed. On ont give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets to other people, even if they have the same medical condition you have. It may harm them. You can ask your pharmacist or doctor for information about rosuvastatin calcium tablets that is written for health professionals. For more information, call 1-800-818-4555. Distributed by: 	
Simplevit 150 mg dD, 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg QD for 7 days Gemfibrozil 600 mg BID for 7 days 80 mg Eltrombopag 75 mg QD, 5 days 10 mg Darunavir 600 mg/ritonavir 100 mg BID, 7 days 10 mg Tipranavir/ritonavir combination 500 mg/200mg BID for 11 days 10 mg Itraconazole 200 mg QD, 5 days 10 mg Itraconazole 200 mg QD, 5 days 10 mg or 80 mg	$\begin{array}{c} 2.69^{2} \\ (2.46 \ to \ 2.94)^{3} \\ (2.59^{2} \\ (2.09 \ to \ 3.21)^{3} \\ (5.26^{2} \\ (1.89 \ to \ 2.69)^{3} \\ (4.2.15^{2} \\ (1.88 \ to \ 2.46)^{3} \\ (4.2.15^{2} \\ (1.7 \ to \ 2.6)^{3} \\ (1.6 \ to \ 2.2)^{2} \\ (1.6 \ to \ 2.2)^{3} \\ (1.6 \ to \ 2.2)^{3} \\ (1.6 \ to \ 2.1)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.4 \ to \ 1.6)^{3} \\ (1.4 \ to \ 1.6)^{3} \\ (1.4 \ to \ 1.6)^{3} \\ (1.1 \ to \ 1.4)^{3} \\ (1.1 \ to \ 1.4)^{3} \\ (1.2 \ to \ 1.6)^{3} \\ (1.2 \ to \ 1$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^2 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 6^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2 \\ (1.8 \text{ to } 2.3)^2 \\ \hline 2.4 \\ (1.6 \text{ to } 3.6)^3 \\ \hline 2.2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2.4 \\ (1.6 \text{ to } 3.6)^3 \\ \hline 2.2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 2.4 \\ (1.6 \text{ to } 1.5)^3 \\ \hline 1.2 \\ \hline 1.2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL- or greater were obser Pediatric use inform (rosuvastatin calciu product is not labele 16 HOW SUPPLI Rosuvastatin calcium 5 mg tablets: Yellow c other side of the table! Bottles of 90 with chill 10 mg tablets: Pink c the other side of thet a	35.5 82.0 16.0	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, he use to rosuvastatin 20 mg to 4 tition from baseline was 22%. 40 mg with further LDL lower emean LDL-C reduction was 2 6, 3 had no change or an increa with known receptor negative s 10.1 rows of age is approver, due to AstraZeneca's marking containing 5 mg, 10 mg, 20 m onvex, film-coated tablets with	11.2 D) -64.9 3) -42.5 Domozygous FH pat 0 mg titrated at a 6- About one-third oft ing of greater than 6 00% (median 28% resein LDL-C. Reduct status. ved for AstraZenec: vet for Astrazenec: ve	2 (8.3, 20.5) 2 (-74.0, -56.6) 4 (-74.0, -56.6) 5 (-47.1, -35.6) 4 tients (n=40, 8 to 5-week interval. In the the patients benefited 6%. In the 27 patients reduction. Among 13 tions in LDL-C of 15% ca's CRESTOR rights, this drug 4 statain. e side and plain on the NDC 47335-582-81 one side and plain on NDC 47335-583-81 one side and plain on	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg). General Information about the safe and effective use of rosuvastatin calcium tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin calcium tablets to other people, even if they have the same medical condition you have. It may harm them. You can ask your pharmacist or doctor for information about rosuvastatin calcium tablets that is written for heading. For more information, call 1-800-818-4555. 	
Sinteprevir 130 nig (D), 7 days single dose Velpatasvir 100 mg once daily 10 mg, single dose Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg once daily Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg QD for 7 days Gemfibrozil 600 mg BID for 7 days 80 mg Eltrombopag 75 mg QD, 5 days 10 mg 0 agys Tipranavir/ritonavir combination 500 mg/200mg BID for 11 days 10 mg Dronedarone 400 mg BID 10 mg Itraconazole 200 mg QD, 5 days 10 mg or 80 mg Ezetimibe 10 mg QD, 14 days 10 mg QD for 14 days	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ to \ 2.94)^{\circ} \\ (2.59^{\circ} \\ (2.09 \ to \ 3.21)^{\circ} \\ (5.26^{\circ} \\ (1.89 \ to \ 2.69)^{\circ} \\ (4.87 \ to \ 2.69)^{\circ} \\ (4.97 \ to \ 2.69)^{\circ} \\ (5.97 \ to \ 2.69)^{\circ} \\ (1.7 \ to \ 2.69)^{\circ} \\ (1.7 \ to \ 2.69)^{\circ} \\ (1.7 \ to \ 2.69)^{\circ} \\ (1.68 \ to \ 2.29)^{\circ} \\ (1.68 \ to \ 2.19)^{\circ} \\ (1.78 \ to \ 2.69)^{\circ} \\ (1.78 \$	$\begin{array}{c} (2.32 \text{ to } 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \text{ to } 9.96)^3 \\ \hline 5.49^3 \\ (4.29 \text{ to } 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \text{ to } 6.59)^3 \\ \hline 5^2 \\ (3.4 \text{ to } 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \text{ to } 2.3)^3 \\ \hline 2.4 \\ (1.6 \text{ to } 3.6)^3 \\ \hline 2.2 \\ (1.8 \text{ to } 2.7)^3 \\ \hline 1.4 \\ (1.2 \text{ to } 1.6)^3 \\ \hline 1.2 \\ (0.9 \text{ to } 1.4)^3 \\ \hline 1.2 \\ (0.8 \text{ to } 1.6)^3 \\ \hline 1.2 \\ (0.8 \text{ to } 1.6)^3 \\ \hline 1.2 \\ (0.8 \text{ to } 1.6)^3 \\ \hline 1.2 \\ \hline 1.2 \\ (0.8 \text{ to } 1.6)^3 \\ \hline 1.2 \\ $	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL-I or greater were obser Pediatric use inform (rosuvastatin calciu) product is not labeled 16 HOW SUPPLI Rosuvastatin calciul 5 mg tablets: Yellow c other side of the table Bottles of 90 with chill 10 mg tablets: Pink c the other side of the table 20 mg tablets: Pink c the other side of the table 20 mg tablets: Pink c the other side of the table 20 mg tablets: Pink c the other side of the table	35.5 82.0 16.0 s Familial Hyperchole y: In an open-labe Jated for their respons name and DL-C reduction dose from 20 mg to 4 adduction in LDL-C, the C reduction of <15%,	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, ho use to rosuvastatin 20 mg to 4 tition from baseline was 22% 4.0 mg with further LDL lower e mean LDL-C reduction was 2 5, 3 had no change or an increa with known receptor negative si to 17 years of age is approv r, due to AstraZeneca's marking containing 5 mg, 10 mg, 20 m onvex, film-coated tablets with	11.2 D) -64.9 3) -42.5 D ong titrated at a 6- About one-third oft ting of greater than 6 30% (median 28% rd se in LDL-C. Reduct status. red for AstraZenec: reting exclusivity ri g or 40 mg of rosuva 'S' debossed on one '583' debossed on of	2 (8.3, 20.5) 9 (-74.0, -56.6) 9 (-74.0, -56.6) 9 (-74.0, -56.6) 1 (-47.1, -35.6) 4 (-47.1, -37.6) 4 (-47.1, -37.6	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredient: rosuvastatin as rosuvastatin calcium fablets? Active Ingredient: colicidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg). General Information about the safe and effective use of rosuvastatin calcium tablets. Do not use rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets to other people, even if they have the same medical condition you have. It may harm them. You can ask your pharmacist or doctor for information about rosuvastatin calcium tablets that is written for health professionals. For more information, call 1-800-818-4555. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Industries Lt	
SimpleverIso ing dD, 7 dayssingle doseVelpatasvir 100 mg once daily10 mg, single doseOmbitasvir 25mg/paritaprevir 150mg/ ritonavir 100 mg + dasabuvir 400 mg BlD5 mg, single doseElbasvir 50 mg/grazoprevir 200 mg once daily10 mg, single doseGlecaprevir 400 mg/pibrentasvir 120 mg once daily5 mg once dailyLopinavir/ritonavir combination 400 mg/100 mg BlD for 17 days20 mg QD for 7 daysGernfibrozil 600 mg BlD for 7 days80 mgEltrombopag 75 mg QD, 5 days10 mg QD for 7 daysTipranavir/ritonavir combination 500 mg/200mg BlD for 11 days10 mg QD for 7 daysTipranavir/ritonavir combination 500 mg/200mg BlD10 mgItraconazole 200 mg QD, 5 days10 mgEtzetimibe 10 mg QD, 5 days10 mg OI for 14 daysFosamprenavir/ritonavir 700 mg/100 mg BlD for 7 days10 mg QD for 14 days	$\begin{array}{c} 2.69^{\circ} \\ (2.46 \ to \ 2.94)^{\circ} \\ (2.59^{\circ} \\ (2.09 \ to \ 3.21)^{\circ} \\ (5.26^{\circ} \\ (1.89 \ to \ 2.69)^{\circ} \\ (4.87 \ to \ 2.69)^{\circ} \\ (4.97 \ to \ 2.69)^{\circ} \\ (5.97 \ to \ 2.69)^{\circ} \\ (1.7 \ to \ 2.69)^{\circ} \\ (1.7 \ to \ 2.69)^{\circ} \\ (1.7 \ to \ 2.69)^{\circ} \\ (1.68 \ to \ 2.29)^{\circ} \\ (1.68 \ to \ 2.19)^{\circ} \\ (1.78 \ to \ 2.69)^{\circ} \\ (1.78 \$	$\begin{array}{c} (2.32 \ to \ 2.92)^3 \\ \hline 7.13^2 \\ (5.11 \ to \ 9.96)^3 \\ \hline 5.69^2 \\ (4.29 \ to \ 7.04)^3 \\ \hline 5.62^2 \\ (4.80 \ to \ 6.59)^3 \\ \hline 5^2 \\ (3.4 \ to \ 6.4)^3 \\ \hline 2.2^2 \\ (1.8 \ to \ 2.7)^2 \\ \hline 2 \\ (1.8 \ to \ 2.7)^2 \\ \hline 2.4 \\ (1.6 \ to \ 3.6)^3 \\ \hline 2.2 \\ (1.8 \ to \ 2.7)^2 \\ \hline 1.4 \\ (1.2 \ to \ 1.5)^3 \\ \hline 1.2 \\ \hline 1.5 \\ \hline 1.2 \end{array}$	HDL-C RLP-C Apo-E 14.5 Homozygous Dose-Titration Stud 63 years) were evalu overall population, th from increasing their with at least a 15% re patients with an LDL-I or greater were obser Pediatric use inform (rosuvastatin calciu) product is not labeled 16 HOW SUPPLI Rosuvastatin calciul 5 mg tablets: Yellow c other side of the table Bottles of 90 with chill 10 mg tablets: Pink c the other side of the table 20 mg tablets: Pink c the other side of the table 20 mg tablets: Pink c the other side of the table 20 mg tablets: Pink c the other side of the table	35.5 82.0 16.0 s Familial Hyperchole dy: In an open-label uated for their respons re mean LDL-C reduct r dose from 20 mg to 4 deduction in LDL-C, the C reduction of <15%, rved in 3 of 5 patients v nation for patients 7 1 im) tablets. However, ed with that pediatric LED/STORAGE AND H in tablets are available of colored, circular, bicor ablet. Id-resistant closure colored, circular, bicor ablet. Id-resistant closure colored, circular, bicor ablet.	10.2 (1.9, 12.3) -56.4 (-67.1, -49.0) -42.9 (-46.3, -33.1) esterolemia el, forced-titration study, ho use to rosuvastatin 20 mg to 4 tition from baseline was 22%. 40 mg with further LDL lower emean LDL-C reduction was 2 6, 3 had no change or an increa with known receptor negative : to 17 years of age is approv r, due to AstraZeneca's mark ic information. HANDLING containing 5 mg, 10 mg, 20 m onvex, film-coated tablets with onvex, film-coated tablets with	11.2 D) -64.9 3) -42.5 D) -64.9 3) -42.5 D) omg titrated at a 6- About one-third oft ting of greater than 6 00% (median 28% resein LDL-C. Reduct status. red for AstraZenec: reting exclusivity ri g or 40 mg of rosuva 'S' debossed on one '583' debossed on one '584' debossed on one 5' debossed on one	2 (8.3, 20.5) 9 (-74.0, -56.6) 9 (-74.0, -56.6) 9 (-74.0, -56.6) 1 (-47.1, -35.6) 4 (-47.1, -37.6) 4 (-47.1, -37.6	 weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin calcium tablets? Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin calcium tablets and all medicines out of the reach of children. What are the Ingredients in Rosuvastatin Calcium Tablets? Active Ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, taic, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg). General Information about the safe and effective use of rosuvastatin calcium tablets. Do not use rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets for a condition for whi	

QD = Once daily, BID = Twice daily, TID = Three times daily, QID = Four times daily 'Single dose unless otherwise noted.

Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)] Mean ratio with 90% CI (with/without coadministered drug, e.g., 1 = no change, 0.7 = 30% decrease,

11 = 11 fold increase in exposure)

Table 5. Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs

Rosuvastatin Dosage Regimen	Coadministered Drug			
		Mean Ratio (ratio with/without coadministered drug) No Effect=1.0		
	Name and Dose	Change in AUC	Change in C	
40 mg QD for 10 days	Warfarin' 25 mg single dose	R-Warfarin 1.0 (1.0 to 1.1) ² S-Warfarin 1.1 (1.0 to 1.1) ²	R-Warfarin 1.0 (0.9 to 1.0) S-Warfarin 1.0 (0.9 to 1.1)	
40 mg QD for 12 days	Digoxin 0.5 mg single dose	1.0 (0.9 to $1.2)^2$	1.0 (0.9 to 1.2)	
40 mg QD for 28 days	Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days	EE 1.3 (1.2 to 1.3) ² NG 1.3 (1.3 to 1.4) ²	EE 1.3 (1.2 to 1.3) NG 1.2 (1.1 to 1.3)	

 EE = ethinyl estradiol, NG = norgestrel, QD = Once daily
 Clinically significant pharmacodynamic effects [see Warnings and Precautions (5.4)]
 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1 = no change, 0.7=30% decrease, 11 = 11-fold increase in exposure)

12.5 Pharmacogenomics Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and other transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 (*SLCO1B1 521T* > *C*). The frequency of this genotype (i.e., *SLCO1B1 521 C/C*) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of rosuvastatin has not been clearly established.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doce

In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not over at lower dagen. seen at lower doses

Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with *Salmonella typhimurium and Escherichia coli*, the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the *in vivo* mouse micronucleus test.

In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6-month treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class. findings have been seen with other drugs in this class.

13.2 Animal Toxicology and/or Pharmacology Central Nervous System Toxicity CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with several other members of this drug class. A chemically similar drug in this class produced dose-dependent optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in dogs, at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose - Edma, bemocrahage, and nartial nercrafts in mean drug level in humans taking the highest recommended dose. Edema, hemorrhage, and partial necrosis in the interstitium of the choroid plexus was observed in a female dog sacrificed moribund at day 24 at 90 mg/kg/day by oral gavage (systemic exposures 100 times the human exposure at 40 mg/day based on AUC). Thigkgrday by oral gavage (systemic exposures too times the number parameters are an equival passed on AUC). Corneal opacity was seen in dogs treated for 52 weeks at 6 mg/kg/day by oral gavage (systemic exposures 20 times the human exposure at 40 mg/day based on AUC). Cataracts were seen in dogs treated for 12 weeks by oral gavage at 30 mg/kg/day (systemic exposures 60 times the human exposure at 40 mg/day based on AUC). Retinal dysplasia and retinal loss were seen in dogs treated for 4 weeks by oral gavage at 90 mg/kg/day (systemic exposures 100 times the human exposure at 40 mg/day based on AUC). Doses \leq 30 mg/kg/day (systemic exposures \leq 60 times the human exposure at 40 mg/day based on AUC) did not reveal retinal findings during treatment for un to one wear treatment for up to one year.

Juvenile Toxicology Study In a juvenile study, rats were dosed by oral gavage with 10 or 50 mg/kg/day from weaning for 9 weeks prior to pairing, throughout pairing and up to the day before necropsy for males or up to gestation day 7 for females. No effects on sexual development, testicular and epididymal appearance or fertility were observed at either dose

Pediatric information is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Skeletal Muscle Effects

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).

Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing rosuvastatin calcium tablets.

Concomitant Use of Antacids When taking rosuvastatin calcium tablets with an aluminum and magnesium hydroxide combination antacid, the antacid should be taken at least 2 hours after rosuvastatin calcium tablets administration.

Embryofetal Toxicity Advise females of reproductive potential of the risk to a fetus, to use effective contraception during treatment, and to inform their healthcare provider of a known or suspected pregnancy [see Contraindications (4) and Use in Specific Populations (8.1, 8.3)].

Lactation Advise women not to breastfeed during treatment with rosuvastatin calcium tablets [see Contraindications (4) and Use in Specific Populations (8.2)].

Liver Enzymes It is recommended that liver enzyme tests be performed before the initiation of rosuvastatin calcium tablets and if signs or symptoms of liver injury occur. All patients treated with rosuvastatin calcium tablets should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.

PATIENT INFORMATION Rosuvastatin (roe-SOO-va-STAT-in) Calcium Tablets

Read this Patient Information carefully before you start taking rosuvastatin calcium tablets and each time you get a refill. If you have any questions about rosuvastatin calcium tablets, ask your doctor. Only your doctor can determine if rosuvastatin calcium tablets are right for you.

It is not known if rosuvastatin calcium tablets are safe and effective in people who have Fredrickson Type

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Rosuvastatin calcium tablets are used to treat:
 adults who cannot control their cholesterol levels by diet and exercise alone

Patients should be instructed not to take 2 doses of rosuvastatin calcium tablets within 12 hours of each other.

FRONT 570 mm SIDE

What are rosuvastatin calcium tablets? Rosuvastatin calcium tablets are a prescription medicine that contains a cholesterol-lowering medicine called rosuvastatin calcium. Rosuvastatin calcium tablets are used along with diet to: o lower the level of your "bad" cholesterol (LDL) o increase the level of your "good" cholesterol (HDL) o lower the level of fat in your blood (triglycerides)

13 NONCLINICAL TOXICOLOGY

Who should not take rosuvastatin calcium tablets?
Do not take rosuvastatin calcium tablets if you:
are allergic to rosuvastatin calcium or any of the ingredients in rosuvastatin calcium tablets. See the end of this leaflet for a complete list of ingredients in rosuvastatin calcium tablets. have liver problems.

have thyroid problems

are of Asian descent

I and V dyslipid

Taking rosuvastatin calcium tablets with certain other medicines may affect each other causing side effects. Rosuvastatin calcium tablets may affect the way other medicines work, and other medicines may affect how

rosuvastatin calcium tablets work.

- anti-viral medicines including certain HIV or hepatitis C virus drugs such as:
 o lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir
- combination of
- sofosbuvir/velpatasvir/voxilaprevir dasabuvir/ombitasvir/paritaprevir/ritonavir
- elbasvir/grazoprevir sofosbuvir/velpatasvir

- glecaprevir/pibrentasvir and
 all other combinations with ledipasvir including ledipasvir/sofosbuvir
 certain anti-fungal medicines (such as itraconazole, ketoconazole and fluconazole)
- coumarin anticoagulants (medicines that prevent blood clots, such as warfarin) Cournann anucoaguants (inductines that prevent blood clots, such as
 niacin or nicotinic acid
 fibric acid derivatives (such as fenofibrate)
 colchicine (a medicine used to treat gout)
 Ask your doctor or pharmacist for a list of these medicines if you are not sure.

2

- Know all of the medicines you take. Keep a list of them to show your doctor and pharmacist when you get new medicine.

KLD_OPEN SIZE: 570 MM X380 MM / CLOSE SIZE : 35X34 MM 11/05/2018

 are pregnant or think you may be pregnant, or are planning to become pregnant. Rosuvastatin calcium tablets may harm your unborn baby. If you become pregnant, stop taking rosuvastatin calcium tablets and call your doctor right away. If you are not planning to become pregnant you should use effective birth control (contraception) while you are taking rosuvastatin calcium tablets.
 are breastfeeding. Medicines like rosuvastatin calcium tablets can pass into your breast milk and may here your bebut harm your baby.

What should I tell my doctor before and while taking rosuvastatin calcium tablets?

Tell your doctor if you: • have unexplained muscle aches or weakness have or have had kidney problems have or have had liver problems
drink more than 2 glasses of alcohol daily • are 65 years of age or older

are pregnant or think you may be pregnant, or are planning to become pregnant
 are breastfeeding

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines,

vitamins, and herbal supplements. Talk to your doctor before you start taking any new medicines.





Rosuvastatin calcium tab

Artwork Type: **PATIENT INFORMATION LEAFLET** Artwork Code: PGPI0167D Void Code: **PGPI0167C** Void A/W Reason: CHANGE IN TEXT AS PER RA DRAFT (RLD Revision, Safety Related Changes) Dimension: 365x235 mm Country: ANDA-US Language: ENGLISH Mfg. Location: DADRA Specification/Type of Paper: SUPER FINE 41 GSM ITC PAPER Folding: **30 Pages pad** Folding: 365 --2 --91.25 mm 235 --0---235 mm Glueing on 235 mm side Special Req.: -Remark (if any):

PATIENT INFORMATION

Rosuvastatin (roe-SOO-va-STAT-in) Calcium Tablets

Read this Patient Information carefully before you start taking rosuvastatin calcium tablets and each time you get a refill. If you have any questions about rosuvastatin calcium tablets, ask your doctor. Only your doctor can determine if rosuvastatin calcium tablets are right for you.

What are rosuvastatin calcium tablets?

Rosuvastatin calcium tablets are a prescription medicine that contains a cholesterol-lowering medicine called rosuvastatin calcium.

- Rosuvastatin calcium tablets are used along with diet to:

 lower the level of your "bad" cholesterol (LDL)
 increase the level of your "good" cholesterol (HDL)
 lower the level of fat in your blood (triglycerides)
- Rosuvastatin calcium tablets are used to treat:
 o adults who cannot control their cholesterol levels by diet and exercise alone

It is not known if rosuvastatin calcium tablets are safe and effective in people who have Fredrickson Type I and V dyslipidemias.

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca's CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Who should not take rosuvastatin calcium tablets? Do not take rosuvastatin calcium tablets if you:

- are allergic to rosuvastatin calcium or any of the ingredients in rosuvastatin calcium tablets. See the end of this leaflet for a complete list of ingredients in rosuvastatin calcium tablets.
- have liver problems.
- are pregnant or think you may be pregnant, or are planning to become pregnant. Rosuvastatin calcium tablets may harm your unborn baby. If you become pregnant, stop taking rosuvastatin calcium tablets and call your doctor right away. If you are not planning to become pregnant you should use effective birth control (contraception) while you are taking rosuvastatin calcium tablets.

Tell your doctor about all the medicines you take, including prescription and overthe-counter medicines, vitamins, and herbal supplements.

Talk to your doctor before you start taking any new medicines. Taking rosuvastatin calcium tablets with certain other medicines may affect each other causing side effects. Rosuvastatin calcium tablets may affect the way other medicines work, and other medicines may affect how rosuvastatin calcium tablets work.

Especially tell your doctor if you take:

- cyclosporine (a medicine for your immune system)
- gemfibrozil (a fibric acid medicine for lowering cholesterol)
- darolutamide (a medicine for the treatment of prostate cancer)
- regorafenib (a medicine used to treat cancer of the colon and rectum)
- anti-viral medicines including certain HIV or hepatitis C virus drugs such as: o lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir o combination of
 - sofosbuvir/velpatasvir/voxilaprevir
 - dasabuvir/ombitasvir/paritaprevir/ritonavir
 - elbasvir/grazoprevir
 sofosbuvir/velpatasvir
 - glecaprevir/pibrentasvir and

o all other combinations with ledipasvir including ledipasvir/sofosbuvir • certain anti-fungal medicines (such as itraconazole, ketoconazole and

fluconazole)

coumarin anticoagulants (medicines that prevent blood clots, such as

- warfarin)niacin or nicotinic acid
- fibric acid derivatives (such as fenofibrate)
- colchicine (a medicine used to treat gout)

Ask your doctor or pharmacist for a list of these medicines if you are not sure. Know all of the medicines you take. Keep a list of them to show your doctor and pharmacist when you get new medicine.

How should I take rosuvastatin calcium tablets?

Take rosuvastatin calcium tablets exactly as your doctor tells you to take it.
Take rosuvastatin calcium tablets, by mouth, 1 time each day. Swallow the tablet whole.

within 12 hours of each other. • If you take too many rosuvastatin calcium tablets or overdose, call your doctor or go to the nearest hospital emergency room right away. What are the Possible Side Effects of Rosuvastatin Calcium Tablets? Rosuvastatin calcium tablets may cause serious side effects, including: • Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. **Tell your doctor right away if:** o you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take rosuvastatin calcium tablets. o you have muscle problems that do not go away even after your doctor has told you to stop taking rosuvastatin calcium tablets. Your doctor may do further tests to diagnose the cause of your muscle problems. Your chances of getting muscle problems are higher if you: o are taking certain other medicines while you take rosuvastatin calcium tablets o are 65 years of age or older o have thyroid problems (hypothyroidism) that are not controlled o have kidney problems o are taking higher doses of rosuvastatin calcium tablets • Liver problems. Your doctor should do blood tests to check your liver before you start taking rosuvastatin calcium tablets and if you have symptoms of liver problems while you take rosuvastatin calcium tablets. Call your doctor right away if you have any of the following symptoms of liver problems: o feel unusually tired or weak o loss of appetite o upper belly pain o dark urine o yellowing of your skin or the whites of your eyes The most common side effects may include: headache muscle aches and

• If you miss a dose of rosuvastatin calcium tablets, take it as soon as you

remember. However, do not take 2 doses of rosuvastatin calcium tablets

Prepared by: SAPNA Checked by:	 are breastfeeding. Medicines like rosuvastatin calcium tablets can pass into your breast milk and may harm your baby. 	 Rosuvastatin calcium tablets can be taken at any time of day, with or without food. 	pains, abdominal pain, weakness, and nausea. Additional side effects that have been reported with rosuvastatin calcium tablets
Approved by: Approved by RA: APPROVAL HISTORY ATTACHED	 What should I tell my doctor before and while taking rosuvastatin calcium tablets? Tell your doctor if you: have unexplained muscle aches or weakness have or have had kidney problems have or have had liver problems 	 Do not change your dose or stop rosuvastatin calcium tablets without talking to your doctor, even if you are feeling well. Your doctor may do blood tests to check your cholesterol levels before and during your treatment with rosuvastatin calcium tablets. Your doctor may change your dose of rosuvastatin calcium tablets if needed. 	include memory loss and confusion. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of rosuvastatin calcium tablets. For more information, ask your doctor or pharmacist.
No. of Colors: 1 Black	 drink more than 2 glasses of alcohol daily have thyroid problems are 65 years of age or older are of Asian descent are pregnant or think you may be pregnant, or are planning to become pregnant are breastfeeding 	 Your doctor may start you on a cholesterol lowering diet before giving you rosuvastatin calcium tablets. Stay on this diet when you take rosuvastatin calcium tablets. Wait at least 2 hours after taking rosuvastatin calcium tablets to take an antacid that contains a combination of aluminum and magnesium hydroxide. 	Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

30 Pages pad Folding: 365291.25 mm 2350235 mm Glueing on 235 mm side		
Su rayes pau		5126. 3038233
Folding:	365 mm	
365291.25 mm		
2350235 mm		
Clusing on 225 mm side		

How should I store rosuvastatin calcium tablets?

Store rosuvastatin calcium tablets at 20° to 25°C (68° to 77°F) and in a dry place.
Safely throw away medicine that is out of date or no longer needed.

Keep rosuvastatin calcium tablets and all medicines out of the reach of children.

What are the Ingredients in Rosuvastatin Calcium Tablets?

Active Ingredient: rosuvastatin as rosuvastatin calcium Inactive Ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized maize starch, talc, titanium dioxide, iron oxide yellow (5 mg), iron oxide red (10 mg, 20 mg, 40 mg), and FD& C Red # 40 aluminum lake (10 mg, 20 mg, 40 mg).

General Information about the safe and effective use of rosuvastatin calcium tablets

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin calcium tablets for a condition for which it was not prescribed. Do not give rosuvastatin calcium tablets to other people, even if they have the same medical condition you have. It may harm them. You can ask your pharmacist or doctor for information about rosuvastatin calcium tablets that is written for health professionals.

For more information, call 1-800-818-4555.

Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512

Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), India.

This Patient Information has been approved by the U.S. Food and Drug Administration. ISS. 09/2020

PGPI0167D

30 Pages pad Folding:		Size: 365x235 mm
Folding:	365 mm	
365291.25 mm		
2350235 mm		
365291.25 mm 2350235 mm Glueing on 235 mm side		